Angelin B, Nilsell K, Einarsson K
Eur J Clin Invest. 1986 Apr;16(2):169-77. doi: 10.1111/j.1365-2362.1986.tb01325.x.
Ursodeoxycholic acid reduces biliary saturation with cholesterol and may induce dissolution of cholesterol gallstones in man. In order to characterize the effects of this potentially useful bile acid on plasma lipid metabolism, we determined lipoprotein levels and very low density lipoprotein (VLDL) triglyceride kinetics in six hypertriglyceridaemic and three normolipidaemic subjects before and after 4-6 weeks of ursodeoxycholic acid treatment at a daily dose of 15 mg kg-1 body weight. The plasma levels of low density lipoprotein (LDL), high density lipoprotein (HDL) and total cholesterol were not significantly affected by therapy. Nor were the plasma level and apparent formation of VLDL triglycerides changed. In five subjects, the effects of a low dose (7.5 mg kg-1 body weight day-1 for 4-6 weeks) of ursodeoxycholic acid on biliary lipid composition and kinetics of cholic acid and chenodeoxycholic acid were determined. The relative concentration of cholesterol in bile was reduced to the same level as during treatment with a high dose of ursodeoxycholic acid. The synthesis rates of bile acids were not suppressed with ursodeoxycholic acid. It is concluded that, unlike chenodeoxycholic acid, ursodeoxycholic acid does not suppress endogenous bile acid production. The efficiency at lower doses, and the lack of effects on plasma lipid metabolism, may make ursodeoxycholic acid a more attractive alternative for clinical attempts of gallstone dissolution.
熊去氧胆酸可降低胆汁中胆固醇的饱和度,并可能促使人体中的胆固醇胆结石溶解。为了明确这种可能有用的胆汁酸对血浆脂质代谢的影响,我们测定了6名高甘油三酯血症患者和3名血脂正常的受试者在每日服用15毫克/千克体重的熊去氧胆酸治疗4至6周前后的脂蛋白水平以及极低密度脂蛋白(VLDL)甘油三酯的动力学。治疗对低密度脂蛋白(LDL)、高密度脂蛋白(HDL)的血浆水平及总胆固醇并无显著影响。VLDL甘油三酯的血浆水平及表观生成量也未改变。我们还测定了5名受试者服用低剂量(每日7.5毫克/千克体重,持续4至6周)熊去氧胆酸对胆汁脂质成分以及胆酸和鹅去氧胆酸动力学的影响。胆汁中胆固醇的相对浓度降低至与高剂量熊去氧胆酸治疗期间相同的水平。熊去氧胆酸并未抑制胆汁酸的合成速率。得出的结论是,与鹅去氧胆酸不同,熊去氧胆酸不会抑制内源性胆汁酸的生成。较低剂量时的有效性以及对血浆脂质代谢无影响,可能使熊去氧胆酸成为胆结石溶解临床尝试中更具吸引力的选择。